Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial
about
Circulating bile acids predict outcome in critically ill patients.Association of serum total bilirubin levels with diastolic dysfunction in heart failure with preserved ejection fraction.Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actionsThe prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure.Liver function predicts survival in patients undergoing extracorporeal membrane oxygenation following cardiovascular surgery.The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registrySignificantly Elevated Liver Alkaline Phosphatase in Congestive Heart Failure.Incorporating common biomarkers into the clinical management of heart failureNoncardiac comorbidities and acute heart failure patients.Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trialDrug-induced liver injury: Do we know everything?Prevalence and importance of comorbidities in patients with heart failure.Co-morbidities in heart failure.Interactions of the heart and the liver.Cardiohepatic syndrome: liver injury in decompensated heart failure.Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure?Cardiohepatic syndrome.Pathophysiology and clinical evaluation of acute heart failure.Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESCBody Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial.Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure.Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF.Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF).Is serum total bilirubin useful to differentiate cardioembolic stroke from other stroke subtypes?Can the liver tell us about the heart? An old story revisited.Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study.Serum cholinesterase is an important prognostic factor in chronic heart failure.Pathophysiology of acute heart failure syndrome: a knowledge gap.Evaluation of a Heart Transplant Candidate.[Pilot study of levosimendan : Effect on liver blood flow and liver function in acute decompensated heart failure].The clinical characteristics and long-term prognosis of pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia.Acute liver failure with extreme hyperbilirubinemia secondary to endocarditis-related severe mitral and tricuspid regurgitation: a challenge and an opportunity for surgeons.Liver-heart crosstalk controls IL-22 activity in cardiac protection after myocardial infarction
P2860
Q33627590-15AA9DA0-9651-4E03-BDC5-25F4DA1028B2Q33913498-91FBF428-DA3D-47EC-84E3-995ADF94E021Q33970136-98DA7FBE-F0E1-4C1A-9269-2E37D5486B88Q34408467-977F6ABC-69CB-466F-B12F-AE7F8D912740Q36679145-6ABDE0C0-650F-427B-A8E5-5E5D66709C5BQ37291800-95CC03A6-63B4-4278-8B2F-8DAD4841DA53Q37311568-B137AD93-BDB2-40E5-93E8-0B76AB6116C7Q37347009-8E47CE57-A379-40EC-8F09-A393E77DE158Q37531314-A7DDACC3-AF6E-410B-A7BA-1C31A78511ADQ37711521-318A6E42-4441-4E4C-9E1B-A244F4033FA8Q37748005-45E3F0D8-6C7B-4DE9-B9EC-BF9091F2B520Q38037383-74F78589-29A8-4895-AFC5-2F760AD06140Q38069787-E7AE103B-BC9F-4FD1-ACCD-744DD93FADCEQ38121525-21C179CC-6CDE-40DD-A2CD-FA7365C5C016Q38217113-CF3BB7A3-9C59-4C5A-B241-7B87AD3B8726Q38220684-5FE434D7-194B-46E9-A1D5-A550316553D3Q38267664-E555A4B7-FC39-4DED-94B7-6B2528510C44Q38586834-74CEB5F6-1E39-4F06-A12A-B513E3B39990Q38676886-14369018-1192-48A6-94E3-6A8B029D227BQ39052397-8855F7DF-A8DF-470F-B519-3F663F798FABQ39317336-7D25A240-79C6-4318-AD37-1B1058FB6912Q40168931-97F18638-2A68-48DF-9574-E014FAD5F4AEQ40231911-0C8FE735-76BF-4F2E-BB45-13B7F80C7DD7Q41043399-80AFDBFA-B362-42CC-84DC-C3E0CE2CBC3BQ43162849-4523ABC7-63C7-4173-9EAD-04F0FB0D1716Q43564400-CFF0AFE5-CFD3-4B15-84B5-AA42EC238F8CQ44317545-07F834F1-D504-4E9E-A5A0-43CB8A1D067BQ48095229-BE969659-2FB9-4B4B-9374-67489F7B0E13Q48561694-F139B725-1AF2-479B-9D4F-0E242629B161Q50457479-B8BF5E73-F9EF-4E19-B22F-C034393EE71DQ53706550-3972F456-9E06-4B1C-9065-64AD3B0C843DQ53833333-7D2FA5B0-4918-4498-8B7F-05C871285F19Q58788939-3DB96AB4-9FD3-4C2E-87B7-9EDA05E2B6DD
P2860
Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial
description
article
@en
im März 2012 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2012
@uk
name
Clinical course and predictive ...... analysis of the EVEREST trial
@en
Clinical course and predictive ...... analysis of the EVEREST trial
@nl
type
label
Clinical course and predictive ...... analysis of the EVEREST trial
@en
Clinical course and predictive ...... analysis of the EVEREST trial
@nl
prefLabel
Clinical course and predictive ...... analysis of the EVEREST trial
@en
Clinical course and predictive ...... analysis of the EVEREST trial
@nl
P2093
P2860
P50
P356
P1476
Clinical course and predictive ...... analysis of the EVEREST trial
@en
P2093
Andrew P. Ambrosy
Angela J. Fought
Mark D. Huffman
Marvin A. Konstam
Mary J. Kwasny
Muthiah Vaduganathan
Sadiya Khan
P2860
P304
P356
10.1093/EURJHF/HFS007
P577
2012-03-01T00:00:00Z